Aurinia Pharmaceuticals Inc
F:IKAP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Aurinia Pharmaceuticals Inc
F:IKAP
|
CA |
|
M
|
Movado Group Inc
F:MV4
|
US |
|
S
|
SBM Offshore NV
XHAM:IHCB
|
NL |
|
Korian SA
F:KO2
|
FR |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
CA |
|
SBM Offshore NV
OTC:SBFFF
|
NL |
|
Carysil Ltd
BSE:524091
|
IN |
|
R E A Holdings PLC
F:BY0
|
UK |
|
K
|
Korian SA
LSE:0OPS
|
FR |
|
N
|
Norwegian Cruise Line Holdings Ltd
SWB:1NC
|
US |
|
SBM Offshore NV
AEX:SBMO
|
NL |
|
A
|
Aurinia Pharmaceuticals Inc
SWB:IKAP
|
CA |
|
K
|
Korian SA
XBER:KO2
|
FR |
Wall St Price Targets
IKAP Price Targets Summary
Aurinia Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for IKAP is 10.13 EUR with a low forecast of 8.85 EUR and a high forecast of 12.88 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IKAP's stock price target?
Price Target
10.13
EUR
According to Wall Street analysts, the average 1-year price target for IKAP is 10.13 EUR with a low forecast of 8.85 EUR and a high forecast of 12.88 EUR.
What is the Revenue forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
16%
Over the last 13 years, the compound annual growth rate for Revenue has been 34%. The projected CAGR for the next 8 years is 16%.
What is the Gross Profit forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
22%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 33%. The projected CAGR for the next 3 years is 22%.
What is the Operating Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
24%
The compound annual growth rate for Operating Income over the next 8 years is 24%.
What is the Pre-Tax Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
33%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 33%.
What is the Net Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
6%
The compound annual growth rate for Net Income over the next 8 years is 6%.
